Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Shares Outstanding data on record, last reported at $42.9 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 45.93% year-over-year to $42.9 million; the TTM value through Sep 2025 reached $42.9 million, up 45.93%, while the annual FY2024 figure was $31.1 million, 109.99% up from the prior year.
  • Shares Outstanding reached $42.9 million in Q3 2025 per DNTH's latest filing, up from $32.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $60.6 million in Q1 2023 and bottomed at $875279.0 in Q2 2022.
  • Average Shares Outstanding over 4 years is $32.6 million, with a median of $31.6 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: tumbled 55.55% in 2023, then soared 109.99% in 2024.
  • A 4-year view of Shares Outstanding shows it stood at $33.3 million in 2022, then tumbled by 55.55% to $14.8 million in 2023, then skyrocketed by 109.99% to $31.1 million in 2024, then skyrocketed by 37.73% to $42.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $42.9 million in Q3 2025, $32.2 million in Q2 2025, and $32.1 million in Q1 2025.